PROJECT

Projects

Summary of Investment Information

Project Number

48927

Company Name

LABORATORIOS SIEGFRIED S.A.S.

Date SPI Disclosed

Jun 6, 2024

Country

Latin America and the Caribbean Region

Region

Latin America and the Caribbean

Projected Board Date

May 13, 2024

Environmental Category

B - Limited

Status

Active

Last Updated Date

Jun 7, 2024

Department

Regional Industry MAS LAC & EUR

Industry

other

Previous Events

Approved : May 21, 2024
Signed : May 24, 2024
Invested : Jun 4, 2024

Sector

other

Project Description

 The proposed IFC investment comprises three loans totaling up to US$315 million equivalent (“the Project”) to three subsidiaries (the “Borrowers”) of Cormoran de Bilbao S.L. (“Roemmers” or the “Group”). The Project will be committed over a period of two years in the form of three senior secured corporate loans, including:

 (i) a US$45 million loan to be disbursed in USD to Laboratorios Siegfried S.A.S. (“Siegfried Colombia”) and Laboratorios Siegfried S.A. (“Siegfried Panama”) to partially finance the acquisition of Activa, S.A de C.V., Activa Energy, S.A. de C.V., and Activa Guatemala, S.A. de C.V. (together “Pharmedic”), a pharmaceutical manufacturing company based in El Salvador with operations in Guatemala, El Salvador, Honduras and Nicaragua (“Phase 1”),

(ii) a US$20 million to be disbursed in Colombian Pesos (c. COP 78.0 billion) to Siegfried Colombia, of which US$5 million (c. COP 19.5 billion) will be own account and US$15 million (c. COP 58.5 billion) mobilized to support its capacity expansion in Colombia through the construction of a new manufacturing facility (“Phase 2”), and

(iii) a US$250 million loan to be disbursed in Mexican Pesos (c. MXN 4.2 billion) to Siegfried Rhein, S.A. de C.V. (“Siegfried Mexico”), of which US$100 million (c. MXN 1.7 billion) will be own account and US$150 million (c. MXN 2.5 billion) mobilized, to support the construction of a new manufacturing facility in Mexico and potential acquisitions in Mexico (“Phase 3”).

Siegfried Colombia, a fully owned subsidiary of Roemmers, is a leading pharmaceutical company focused on the development, manufacture and commercialization of over-the-counter medicines, prescription drugs and personal care products (mostly branded generics). With two manufacturing plants in Colombia and 840 employees, Siegfried Colombia is focused mainly on cardio, neuro, women’s health, and primary care therapeutic areas. Approximately 95% of Siegfried Colombia’s revenues are generated in Colombia, and the rest is exported to Central America, Ecuador, and Peru.

Founded 45 years ago, Siegfried Mexico is a Mexico-based, pharmaceutical company fully owned by Roemmers focused on the development, manufacture, and commercialization of branded generic medicines. Siegfried Mexico (and its affiliates in Mexico) owns two manufacturing facilities located in Queretaro, Mexico. It is one of the leading domestic pharmaceutical companies in Mexico, primarily focused on prescription generics, with a portfolio of over 100 brands covering the following therapeutic areas: analgesics, antibiotics, cardiovascular, gastrointestinal, women’s health, central nervous system, and pediatrics. The Company has one of the largest pharmaceutical sales forces in Mexico and employs more than 1,600 people.

                                                  

Associated Advisory Engagement

 IFC will leverage its extensive industry expertise on a global scale to support Roemmers in the development for its two new manufacturing facilities in Colombia and Mexico.

In Colombia, IFC will continue to provide advice and support Roemmers in the construction of its new plant to ensure it integrates recommendations on plant’s design as well as accompaniment in obtaining EDGE Green Building certification for its new facility. Complementary and recognizing on Siegfried Colombia’s efforts to address gender disparities and promote inclusion, and with support of IFC's Gender & Workforce Platform advisory services, Siegfried Colombia will undergo EDGE Gender “Assess” re-certification, while seeking to upgrade its certification to EDGE Gender “Move” level and become the only healthcare organization certified in Latin America (“LAC”) and the second globally at that level.

Siegfried Rhein has expressed its interest in receiving support from IFC in implementing resource efficiency improvements to its existing plant, as well as in obtaining EDGE green building certification for its new manufacturing facility. In terms of Gender Advisory support, IFC has met with Siegfried Mexico’s management to discuss potential support on this front. In light of this financing project, IFC is seeking to guide Siegfried Mexico in achieving inclusive recruitment objectives and explore the possibility of obtaining the EDGEplus Gender Certification.                                                   

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation